Biogen extends losses as Wall Street weighs in on Medicare decision on Aduhelm

Jan. 12, 2022 7:25 AM ETBiogen Inc. (BIIB), ESALY, ESALFRHHBY, LLY, HHSBy: Dulan Lokuwithana, SA News Editor12 Comments

Alzheimers Concept Horizontal

travellinglight/iStock via Getty Images

  • Biogen (NASDAQ:BIIB) has extended post-market losses to trade ~9.9% lower in early trading after the U.S. government announced its decision on Tuesday to severely restrict the access to Aduhelm and other similar Alzheimer’s drugs only

Recommended For You

Comments (12)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.